Analyze and assess the spectral, DFT, and medicinal characteristics through targeted pharmacological investigation of 2-(3-(5-(4-chlorophenyl)furan-2-yl)acryloyl)-3,4-dihydro-2H-naphthalen-1-one (CHFADN)

Abstract

The compound 2-(3-(5-(4-chlorophenyl)furan-2-yl)acryloyl)-3,4-dihydro-2H-naphthalen-1-one (CHFADN) was synthesized using the Claisen-Schmidt condensation method, reacting aromatic aldehydes with methyl ketones. Characterization was performed using NMR, FTIR, and UV–visible spectroscopy. A theoretical model was developed with Gaussian 09 software, utilizing the B3LYP/6–311++G(d,p) basis set, to investigate geometric, electronic, and spectroscopic properties, including geometry optimization, harmonic vibration simulations, molecular electrostatic potential (MEP), frontier molecular orbitals (FMOs), and Mulliken's population analysis. A scaling factor of 0.9600 ensured alignment between the compound's vibrational spectrum and the experimental IR spectrum.In-vitro testing showed notable bactericidal efficacy,H2O2 scavenging activity and antidiabetic activity. In silico molecular docking using AutoDock 4.0, focusing on the 1HD2 protein's active pocket, revealed a binding interaction energy of -6.5 kcal/mol. ADME properties were predicted based on retention data (RM0). The compound showed no mutagenic effects in toxicity testing, indicating a promising safety profile for new drug candidates.